Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2009  |  Volume : 5  |  Issue : 4  |  Page : 272-276

Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer


1 Department of Medical Oncology, Centre Leon Berard, Lyon France; Department of Medical Oncology, Institut National d'Oncologie Sidi Mohamed Ben Abdellah, Rabat, Morocco
2 Department of Medical Oncology, Centre Leon Berard, Lyon France
3 Biostatistics Unit, Centre Leon Berard, Lyon France
4 Department of Medical Oncology, Institut National d'Oncologie Sidi Mohamed Ben Abdellah, Rabat, Morocco

Correspondence Address:
Hind Mrabti
14 Rue Moulay Yaacoub, Av Ain Khalwiya, Souissi, Rabat, Morocco

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.59907

Rights and Permissions

Aim : The aim of the present study was to compare the efficacy and safety of weekly versus an every 2-week administration of cetuximab in association with irinotecan in patients with metastatic colorectal cancer (MCRC). Methods : We reviewed the clinical records of 50 patients with MCRC who began treatment with cetuximab from February 2004 to January 2007. Two different treatment schedules were used. In the first group (N = 32), cetuximab was given at an initial dose of 400 mg/m 2 , followed by weekly infusions of 250 mg/m 2 . In the second group (N = 18), cetuximab was administered every 2 weeks at a dose of 500 mg/m 2 . The two groups were compared for tumor response, time to progression (TTP), overall survival (OS), and toxicity. Results : All patients had received irinotecan and 5-fluorouracil; a majority had previously received oxaliplatin. Disease control (partial response + stable disease) was achieved in 56.3% of patients receiving weekly cetuximab versus 77.8% in the other group (P = 0.21). The median follow-up for all patients was 34.2 months. TTP (Group 1: 28% vs. Group 2: 18%, P = 0.9356) and OS (Group 1: 75% vs. Group 2: 72%, P = 0.6748) rates at 7 months were similar in the two groups. Skin toxicity was the most relevant adverse event: 78.1% of the patients had acne-like rash in the first group and 61% in the second group. However, only one patient in each group had a grade 3 toxic reaction. Conclusion : There is no major difference of efficacy and safety between cetuximab given every 2 weeks and a weekly dosing regimen, in association with irinotecan.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9857    
    Printed254    
    Emailed4    
    PDF Downloaded555    
    Comments [Add]    
    Cited by others 7    

Recommend this journal